Oppenheimer Reaffirms Hold Rating for bluebird bio (BLUE)

Oppenheimer reissued their hold rating on shares of bluebird bio (NASDAQ:BLUE) in a research note published on Friday morning.

BLUE has been the subject of a number of other reports. Wedbush cut their price objective on bluebird bio from $204.00 to $166.00 and set an outperform rating for the company in a research report on Monday, November 5th. Janney Montgomery Scott upgraded bluebird bio from a neutral rating to a buy rating and set a $170.00 price objective for the company in a research report on Monday, November 5th. BidaskClub upgraded bluebird bio from a strong sell rating to a sell rating in a research report on Friday, November 30th. Morgan Stanley cut their price objective on bluebird bio from $186.00 to $185.00 and set an equal weight rating for the company in a research report on Monday, November 5th. Finally, JPMorgan Chase & Co. restated a buy rating on shares of bluebird bio in a research report on Thursday. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $188.83.

Shares of bluebird bio stock traded down $1.61 on Friday, reaching $115.28. The company’s stock had a trading volume of 405,728 shares, compared to its average volume of 574,441. The stock has a market capitalization of $6.03 billion, a PE ratio of -14.95 and a beta of 2.41. bluebird bio has a 52-week low of $87.49 and a 52-week high of $236.17.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings data on Thursday, November 1st. The biotechnology company reported ($2.73) EPS for the quarter, beating the Zacks’ consensus estimate of ($2.90) by $0.17. The business had revenue of $11.50 million during the quarter, compared to analysts’ expectations of $6.90 million. bluebird bio had a negative return on equity of 31.50% and a negative net margin of 1,326.02%. The business’s revenue was up 49.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.73) earnings per share. Equities analysts forecast that bluebird bio will post -10.76 EPS for the current fiscal year.

In other bluebird bio news, insider David Davidson sold 5,000 shares of the company’s stock in a transaction on Friday, November 2nd. The stock was sold at an average price of $133.64, for a total value of $668,200.00. Following the completion of the sale, the insider now directly owns 29,905 shares in the company, valued at approximately $3,996,504.20. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Philip D. Gregory sold 1,800 shares of the company’s stock in a transaction on Monday, November 5th. The shares were sold at an average price of $137.38, for a total value of $247,284.00. Following the completion of the sale, the insider now owns 31,971 shares of the company’s stock, valued at $4,392,175.98. The disclosure for this sale can be found here. Insiders have sold 28,777 shares of company stock valued at $3,290,502 over the last quarter. 3.00% of the stock is owned by company insiders.

A number of large investors have recently modified their holdings of the business. State of Alaska Department of Revenue grew its holdings in bluebird bio by 9.2% in the 3rd quarter. State of Alaska Department of Revenue now owns 6,320 shares of the biotechnology company’s stock valued at $922,000 after buying an additional 530 shares in the last quarter. Dynamic Technology Lab Private Ltd grew its holdings in bluebird bio by 43.2% in the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 2,040 shares of the biotechnology company’s stock valued at $320,000 after buying an additional 615 shares in the last quarter. Stratos Wealth Partners LTD. purchased a new stake in bluebird bio in the 3rd quarter valued at $106,000. Belpointe Asset Management LLC purchased a new stake in bluebird bio in the 3rd quarter valued at $110,000. Finally, Utah Retirement Systems grew its holdings in bluebird bio by 8.6% in the 3rd quarter. Utah Retirement Systems now owns 10,100 shares of the biotechnology company’s stock valued at $1,475,000 after buying an additional 800 shares in the last quarter.

About bluebird bio

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

Read More: What does the Dow Jones Industrial Average (DJIA) measure?

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply